South & Central America Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User

The South & Central America glioma treatment market is expected to grow from US$ 117.14 million in 2022 to US$ 227.74 million by 2030. It is estimated to grow at a CAGR of 8.7% from 2022 to 2030.

Increasing Opportunities in Emerging Economies Fuels South & Central America Glioma Treatment Market

Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies in the world. The healthcare sectors in these countries, as well as other developing economies, are projected to expand rapidly in the coming years. The expected growth is ascribed to changes in customer demand, an increase in awareness about healthcare services, and a continuous rise in the aging population. The global brain cancer diagnostics market is likely to grow significantly in the coming years with the proliferation of the healthcare sector. Further, increased government spending on healthcare facilities and consumer purchasing power contribute to the growth of the healthcare sector in developing countries.

20 years before the COVID-19 epidemic, health service coverage in the Americas region improved, albeit slowly. Compared to 65% of people in 2000, 77% of people in 2019 had health insurance. Government spending on health expanded by 1.1 percentage points while the number of health personnel increased. Thus, the growing healthcare sector in the region creates opportunities for the glioma treatment market players to expand their business.

South & Central America Glioma Treatment Market Overview

The glioma treatment market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The market growth in this region is ascribed to the rising incidence of brain cancer and a spur in developments in healthcare systems. In addition, the universities in Latin American countries are collaborating with various private and public companies to support studies related to brain cancer treatment. The rising awareness about neurovascular disorders is also favoring the glioma treatment market in South & Central America.

Brazil is the fifth largest country in the world by area and population and is experiencing the fastest demographic aging as per the world data.info. As per the Globocan 2020 report, brain cancer is the most common cause of death in Brazil. 12,260 new cases of brain cancer were reported in Brazil in 2020, while brain and CNS cancers led to 10,920 deaths. Further, the 5-year prevalence rate of brain cancer in Brazil for all ages is ~15.17 per 100,000 population. The number of cancer cases in Argentina is increasing at a steady rate. According to the Globocan report published by the Global Cancer Observatory of the WHO, ~1,831 new cases of brain cancer were diagnosed in 2020, of which 1,488 deaths were reported due to brain cancer in Argentina. The 5-years prevalence rate of brain cancer for all age groups was found to be 11.62 per 100,000 population in Argentina.

Chile, Colombia, Peru, Cuba, Venezuela, and Bolivia are among other the key contributors to the glioma treatment market in South & Central America. These countries are improving their healthcare infrastructure by allowing new market players to enter into the marketplace. In addition, the countries in the Rest of South & Central America are investing and taking an interest in improving their healthcare research activities and adopting advanced therapies for brain cancer.

South & Central America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Glioma Treatment Market Segmentation

The South & Central America glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the South & Central America glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the South & Central America glioma treatment market in 2022.

Based on treatment type, the South & Central America glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the South & Central America glioma treatment market in 2022.

Based on grade, the South & Central America glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the South & Central America glioma treatment market in 2022.

Based on end user, the South & Central America glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the South & Central America glioma treatment market in 2022.

Based on country, the South & Central America glioma treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America glioma treatment market in 2022.

Amgen Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the South & Central America glioma treatment market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America Glioma Treatment market.
• Highlights key in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the South & Central America Glioma Treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.